- Poster presentation
- Open Access
Efficacy of abatacept in juvenile idiopathic arthritis related uveitis
© Katargina et al; licensee BioMed Central Ltd. 2011
- Published: 14 September 2011
- Juvenile Idiopathic Arthritis
Despite various immunosuppressive agents, juvenile idiopathic arthritis (JIA) related uveitis often take a serious course that leads to sight threatening complications.
To evaluate efficacy of Abatacept in combined treatment of JIA related uveitis.
10 children aged 4 – 12 years with anterior uveitis associated with JIA were treated by Abatacept in standard infusions pattern and doses. Indication for using Abataceptwas ineffectiveness of standard therapy of arthritis and/or uveitis. 6 patients were suffering from polyarticular variants, 4 – oligoarticular JIA. Abatacept was combined with Methotrexate in 9, Sulfasalazin in 1 and low-dose steroids in 4 children. 3 patients were switched to Abatacept from Infliximab due to non-efficacy, 7 received abatacept as a first line biologic. 9 patients had bilateral eye involvement. At the administration of Abatacept severe inflammation was seen in 1, moderate in 7, mild in 2 of the cases. Follow up period ranged from 3 to 11 month (mean 7.6). The main outcome measure was the degree of inflammation.
Remission of uveitis in current treatment was achieved in 6 (60%), improvement in the degree of inflammation in 2 (20%) of the cases. The initial response was seen after the 2nd – 4th injection. From patients switched from Infliximab to Abatacept 1 achieved remission of uveitis, 1 improved, 1 remained stable. Patients with remission of uveitis diminished or discontinued topical medications. No ocular or systemic adverse effects were observed. Glaucoma or cataract surgery was uncomplicated in all 4 cases.
Administration of Abatacept was effective in 80% of children with JIA related uveitis. Further investigations are required to define clear indications for this treatment in severe uveitis.
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.